These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34593152)

  • 1. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer.
    Huang DQ; Kew GS; Lim SG
    Clin Liver Dis; 2021 Nov; 25(4):763-784. PubMed ID: 34593152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
    Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers.
    O'Neil CR; Congly SE; Rose MS; Lee SS; Borman MA; Charlton CL; Osiowy C; Swain MG; Burak KW; Coffin CS
    Ann Hepatol; 2018; 17(2):232-241. PubMed ID: 31097238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
    Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
    Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
    Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
    J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.
    Kim BK; Han KH; Ahn SH
    Digestion; 2011; 84 Suppl 1():29-34. PubMed ID: 22156483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.
    Wang CC; Tseng TC; Wang PC; Lin HH; Kao JH
    J Formos Med Assoc; 2014 Nov; 113(11):786-93. PubMed ID: 23911291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine.
    Colombatto P; Coco B; Bonino F; Brunetto MR
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
    Seo Y; Yano Y
    World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
    Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
    Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
    Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
    World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
    J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.